Cargando…
Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III trial for recurrent glioblastomas, NovoTTF-100A was shown to have equivalent efficacy and less toxicity when compared to Best Physician's Choice (BPC) chemotherapy. We...
Autores principales: | Wong, Eric T, Lok, Edwin, Swanson, Kenneth D, Gautam, Shiva, Engelhard, Herbert H, Lieberman, Frank, Taillibert, Sophie, Ram, Zvi, Villano, John L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101750/ https://www.ncbi.nlm.nih.gov/pubmed/24574359 http://dx.doi.org/10.1002/cam4.210 |
Ejemplares similares
-
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation
por: Wong, Eric T, et al.
Publicado: (2015) -
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
por: Swanson, Kenneth D., et al.
Publicado: (2016) -
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system
por: Turner, Scott G, et al.
Publicado: (2014) -
NovoTTF(™)-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL(™) system user study
por: Chaudhry, Aafia, et al.
Publicado: (2015) -
PEDT-9 A study of NovoTTF-100A to expand the regulatory indication for childhood glioblastoma through a pediatric clinical trial based on the Advanced Medical Care system
por: Yuza, Yuki, et al.
Publicado: (2021)